StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Rajesh Palviya, Axis Securities

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Swing (≤2wk))10 Jun 2026via CNBC Awaaz.

Entry₹1,115.4Inferred
Target₹1,200
Total upside +7.58% (call closed)
Stop loss₹1,075-3.62% risk
Exit₹1,07516 Jun 2026, 11:30 am
Stop-loss hit-3.62%
Follow Rajesh Palviya for new calls(27% target hit, 178 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 9:35 pm IST
2 supporting1 neutral0 opposing
Supports the BUY call (2)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·8 Jun · 1w ago

Zydus Lifesciences Limited's New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) has been granted Priority Review by the US FDA.

NSE · Press Release·28 May · 3w ago

(opens in new tab)
Neutral / worth noting (1)

Zydus Lifesciences Ltd has issued an addendum to its public announcement regarding the buyback of equity shares.

BSE · Company Update·27 May · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Rajesh Palviya, Axis Securities

Every call and its outcome